Sort
25,944 grants matching “neurodegeneration”
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency
$714,043Jonathan Karn · Case Western Reserve University · R01 · FY2017 · DA
Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment
$713,970Xiangrong Shi · University Of North Texas Hlth Sci Ctr · R01 · FY2023 · AG
Core B: Clinical Core
$713,909Benjamin Michael Hampstead · University Of Michigan At Ann Arbor · P30 · FY2024 · AG
Endolysosomal defects in secretory autophagy and microglial toxicity in FTD
$713,896Eric J Huang · University Of California, San Francisco · R01 · FY2023 · AG
Endolysosomal defects in secretory autophagy and microglial toxicity in FTD
$713,896Eric J Huang · University Of California, San Francisco · R01 · FY2024 · AG
Endolysosomal defects in secretory autophagy and microglial toxicity in FTD
$713,896Eric J Huang · University Of California, San Francisco · R01 · FY2022 · AG
Role of slow waves and sleep apnea in memory and risk for Alzheimer disease
$713,857Andrew W Varga · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · AG
BD FACSDiscover S8 Image-Enabled Spectral Cell Sorter
$713,643Emmanuelle Passegue · Columbia University Health Sciences · S10 · FY2024 · OD
AAV capsid engineering for enhancing gene transfer
$713,439Mark A Kay · Stanford University · R01 · FY2020 · AI
Biomarker Core
$713,424Adam M Brickman · Columbia University Health Sciences · P30 · FY2025 · AG
Causes and consequences of differential APP processing in inhibitory and excitatory neurons
$713,402Joanna L Jankowsky · Baylor College Of Medicine · R01 · FY2024 · AG
Deciphering the molecular interplay of sleep and neurodegeneration with Drosophila
$712,984Matthew S Kayser · University Of Pennsylvania · R56 · FY2021 · AG
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
$712,883Vilmundur Gudnason · Icelandic Heart Association · R01 · FY2021 · AG
Mitoribosome protein translation signaling and survival mechanisms
$712,792Pere Puigserver · Dana-Farber Cancer Inst · R01 · FY2025 · AG
Characterizing persistent subclinical neurobehavioral effects of COVID-19 in a diverse urban population
$712,681Michael Lawrence Lipton · Albert Einstein College Of Medicine · R01 · FY2022 · NS
In vivo Identification of Pre-Atrophic Brain Neurodegeneration in Prodromal Alzheimer Disease with Quantitative Gradient Recalled Echo MRI
$712,467Dmitriy A Yablonskiy · Washington University · R01 · FY2025 · AG
Disentangling the contribution of tau to aging and AD
$712,125Keith A. Johnson · Massachusetts General Hospital · R01 · FY2018 · AG
Disentangling the contribution of tau to aging and AD
$712,125Keith A. Johnson · Massachusetts General Hospital · R01 · FY2016 · AG
Disentangling the contribution of tau to aging and AD
$712,125Keith A. Johnson · Massachusetts General Hospital · R01 · FY2014 · AG
Disentangling the contribution of tau to aging and AD
$712,125Keith A. Johnson · Massachusetts General Hospital · R01 · FY2017 · AG
Reserve against Disability in Early Multiple Sclerosis (RADIEMS) Longitudinal Cohort Study
$712,098James Francis Sumowski · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · HD
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology
$712,064Thota Ganesh · Emory University · U01 · FY2020 · AG
Transposable Element (TE) RNA regulation via small RNA pathways in aging cells and neurodegeneration.
$712,052Nelson C Lau · Boston University Medical Campus · R01 · FY2023 · AG
Neurobiology Core
$711,950Cristian L Achim · University Of California, San Diego · P30 · FY2020 · MH
CH25H mediates microglial neuroinflammation and tau toxicities in AD
$711,898Wenjie Luo · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · AG